# A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

> **NCT00951275** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 105 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]
- **DRUG:** Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)

## Key facts

- **NCT ID:** NCT00951275
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-31
- **Primary completion:** 2011-07-22
- **Final completion:** 2011-07-22
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2017-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00951275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00951275, "A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00951275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*